Compare Hormel Foods Corp (HRL) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs Medtronic PLC — how do they compare? Hormel Foods Corp trades at $23.96 (market cap $13.37B), while Medtronic PLC trades at $88.93 (market cap $116.07B). The key difference: Medtronic PLC is far larger — about 8.7× Hormel Foods Corp's market cap, and Hormel Foods Corp pays the higher dividend (4.81%). Which is the better fit depends on your goals.
| HRL | MDT | |
|---|---|---|
Market Cap | $13.37B | $116.07B |
Sector | Consumer Staples | Health |
52-Week High | $29.25 | $105.35 |
52-Week Low | $19.74 | $73.75 |
Enterprise Value | $15.37B | $134.82B |
Dividend Yield | 4.81% | 3.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $24.705, down 1.26% on the day, with a bearish technical signal and neutral oscillators. The company reported Q2 2026 EPS of $0.40, beating expectations, but net income margin declined to 3.82% in 2025. Recent news includes the appointment of John Ghingo as CEO and the sale of its Brazilian CERATTI business, signaling strategic refocusing.
Outlook is mixed: strong dividend yield and consistent earnings beats support income investors, but margin pressures and bearish technicals pose near-term risks. Analyst consensus is 'Hold' with a $26.33 price target, suggesting limited upside. Macroeconomic headwinds in consumer staples may challenge growth.
Medtronic (MDT) trades at $89.41, up 2.58% on the day, reflecting positive momentum. The stock exhibits bullish technical signals with strong moving average support and a consensus analyst price target of $98.75. Fundamentally, the company reported revenue of $33.54B for 2025 with a net income margin of 13.2%, and has consistently beaten EPS estimates in recent quarters. Recent news highlights institutional acquisitions and positive developments in medical technology platforms.
The outlook for MDT is positive, driven by earnings beats, robust cash flow, and growth in cardiac and robotic surgery segments. Key opportunities include undervaluation relative to analyst targets and dividend stability. Risks involve rising debt levels and competitive pressures in the medtech sector. The stock presents a compelling case for growth-oriented income investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
